Loading
A phase 2 trial of MEN1703, Glofitamab in hodgkin lymphoma and non-hodgkin lymphoma, run by Ryvu Therapeutics SA, now recruiting.
MEN1703 (SEL24) to Treat Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma (JASPIS-01) is a phase 2 interventional study registered as NCT06534437 by Ryvu Therapeutics SA, with 178 participants planned, started 2024-12-05 and due to reach its primary completion in 2026-12. Interventions recorded: MEN1703, Glofitamab. Conditions listed: Non-Hodgkin Lymphoma, B-cell. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Glofitamab, T-cell engagers (bispecific), Hodgkin lymphoma, Non-Hodgkin lymphoma (all types).
Shares Glofitamab, T-cell engagers (bispecific), Hodgkin lymphoma.
Shares T-cell engagers (bispecific), Hodgkin lymphoma, Non-Hodgkin lymphoma (all types).
Shares Glofitamab, T-cell engagers (bispecific), Non-Hodgkin lymphoma (all types).
Shares Glofitamab, T-cell engagers (bispecific), Non-Hodgkin lymphoma (all types).
Shares Glofitamab, T-cell engagers (bispecific), Non-Hodgkin lymphoma (all types).
Shares Glofitamab, Hodgkin lymphoma, Non-Hodgkin lymphoma (all types).
Shares Glofitamab, T-cell engagers (bispecific), Hodgkin lymphoma.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/